聚乙二醇干扰素与拉米夫定治疗HBeAg阳性慢性乙型肝炎疗效比较  

Pegylated interferon and lamivudine treatment of HBeAg-positive chronic hepatitis B treatment comparative analysis

作　　者：陈文平 

机构地区：[1]陕西省汉中市汉江职工医院药剂科,陕西汉中723003

出　　处：《海南医学院学报》2011年第9期1189-1191,共3页Journal of Hainan Medical University

基　　金：海南医学院科研基金资助学报项目(0020110310)~~

摘　　要：目的:比较聚乙二醇干扰素与拉米夫定治疗HBeAg阳性慢性乙型肝炎疗效,为临床药物治疗提供参考。方法:HBeAg阳性慢性乙型肝炎患者80例,随机分为观察组与对照组,每组40例,两组均经综合保肝治疗,对照组加用拉米夫定治疗,观察组加用聚乙二醇干扰素治疗,比较治疗前、后两组肝功能指标丙氨酸转氨酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)的水平,以及HBeAg/HBeAb血清转换与HBV DNA转阴情况。结果:两组治疗前ALT、TBIL、ALB水平无明显差异(P均>0.05),治疗后两组各指标都有明显下降(P<0.05),观察组下降幅度明显大于对照组(P均<0.05);治疗后观察组的HBeAg/HBeAb血清转换率(30.0%)与HBV DNA转阴率(80.0%)明显高于对照组(15.0%、40.0%),差异有统计学意义(P均<0.05)。结论:聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎能有效改善肝功能状态,同时提高HBeAg/HBeAb血清转换率与HBV DNA转阴率,值得推广应用。Objective： To observe the pegylated interferon and lamivudine treatment of HBeAg-positive chronic hepatitis B treatment comparison to provide reference for clinical drug treatment.Methods： HBeAg-positive chronic hepatitis B of 80 patients divided into two groups according to admission order level-the treatment group and control group 40 cases.Liver in both groups after combined treatment with lamivudine plus control group,the control group were treated with pegylated interferon therapy.Results： The two groups before treatment liver function（ALT,TBIL,ALB） and other contrast was no significant difference（P0.05）,after treatment,has decreased significantly（P0.05）,but the decline in the treatment group was significantly higher in the control group（P0.05）.After treatment,the treatment group HbeAg / HbeAb seroconversion rate and HBV DNA negative conversion rates were 30.0% and 80.0%,while the control group were 15.0% and 40.0%.Treatment group HbeAg/HbeAb seroconversion rate and HBV DNA negative rate was significantly higher,the difference was significant difference（P0.05）.Conclusion： Compared with interferon,the lamivudine treatment of HBeAg-positive chronic hepatitis B can improve liver function,while increasing HbeAg / HbeAb seroconversion and HBV DNA negative conversion rate,should be widely applied.

关 键 词：HBEAG阳性慢性乙型肝炎 聚乙二醇干扰素 拉米夫定 血清转换率 

分 类 号：R512.62[医药卫生—内科学]